Reviva Pharmaceuticals Holdings, Inc.

USD

1.71

	Feb '20	Dec '20	Dec '21	Dec '22
net income	-846.83K -	-3.78M 346.77%	-8.52M 125.24%	-24.34M 185.61%
depreciation and amortization	645 -	591 8.37%
deferred income tax
stock based compensation			106.71K -	176.74K 65.62%
change in working capital	634.15K -	-2.33M 467.35%	-702.17K 69.86%	5.01M 813.11%
accounts receivables
inventory
accounts payables	158.17K -	775.10K 390.04%	-498.46K 164.31%	3.01M 703.99%
other working capital	475.98K -	-3.10M 752.27%	-203.71K 93.44%	2.00M 1,080.11%
other non cash items	-6.41K -	2.39M 37,339.26%	-1.55M 164.99%	194.71K 112.55%
net cash provided by operating activities	-218.44K -	-3.73M 1,605.56%	-10.67M 186.35%	-18.96M 77.73%
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
debt repayment
common stock issued			31.50M -	7.77M 75.32%
common stock repurchased
dividends paid
other financing activites		12.49M -	98.48K 99.21%	18.97K 80.74%
net cash used provided by financing activities	100K -	12.49M 12,385.96%	31.60M 153.05%	7.79M 75.34%
effect of forex changes on cash
net change in cash	-118.44K -	8.76M 7,496.13%	20.93M 138.89%	-11.17M 153.37%
cash at beginning of period	118.64K -	193 99.84%	8.76M 4,538,999.48%	29.69M 238.89%
cash at end of period	193 -	8.76M 4,538,999.48%	29.69M 238.89%	18.52M 37.62%
operating cash flow	-218.44K -	-3.73M 1,605.56%	-10.67M 186.35%	-18.96M 77.73%
capital expenditure
free cash flow	-218.44K -	-3.73M 1,605.56%	-10.67M 186.35%	-18.96M 77.73%

All numbers in USD (except ratios and percentages)